NCT
HOME CURRENT ARCHIVE COVID-19
HOME CURRENT ARCHIVE PUBLISH INSTRUCTIONS
FOR AUTHORS COVID-19 LOG IN / REGISTER HISTORY ABOUT US DIRECTORY CONTACT
Molecular profile tumor of pulmonary cancer measured by next generation sequencing

Sánchez-Ríos, Carla Paola; Flores-Soto, María del Rosario; Rodríguez-Cid, Jerónimo Rafael; Martínez-Barrera, Luis Manuel; Santillán-Doherty, Patricio; Alatorre-Alexander, Jorge Arturo





2020, Number 1

2020; 79 (1)






ABSTRACT

Introduction: Lung cancer is the leading cause of cancer death worldwide, showing an increase in women and non-smokers in the last decade. Currently, the diagnostic-therapeutic approach is being studied with the knowledge of the heterogeneity of tumors and the optimization in molecular analysis with novel techniques such as genetic sequencing. Material and methods: A cross-sectional and descriptive study was carried out. We included 112 patients with clinical stage IV non-small cell lung cancer. Relevant regions for the search for cancer-associated mutations in 15 genes were analyzed in tumor tissue samples and subsequently a univariate descriptive analysis was performed. Results: A higher frequency of mutations was observed in TP53 (64.3%), followed by 32 subjects (28.6%) with mutation in EGFR and 29 subjects (25.9%) with mutation in ERBB2. Followed in order of frequency KRAS, PIK3CA, KIT, BRAF NRAS. No mutations were found in AKT and MET. Conclusions: We corroborated by sequencing of new generation the approximate frequency reported of mutations in EGFR and its association with antecedent of smoking and the female gender as it has been established in the international literature.

KEYWORDS

Lung cancer, next generation sequencing, prognosis.

REFERENCES

  1. Arrieta O, Guzmán de Alba E, Alba López LF, et al. Consenso Nacional de Diagnóstico y Tratamiento del cáncer de pulmón de células no pequeñas. Rev Invest Clin 2013;65(Supl.1):s5-s84.

  2. Sharma SV, Settleman J. ErbBs in lung cancer. Exp Cell Res 2009;315(4):557-571. doi: 10.1016/j.yexcr.2008.07.026.

  3. Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 2010;28(36):5311-5320. doi: 10.1200/JCO.2010.28.8126.

  4. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-1703. doi: 10.1056/NEJMoa1006448.

  5. Schuurbiers OC, Looijen-Salamon MG, Ligtenberg MJ, van der Heijden HF. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates. J Thorac Oncol 2010;5(10):1664-1667. doi: 10.1097/JTO.0b013e3181f0bd93.

  6. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29(15):2121-2127. doi: 10.1200/JCO.2010.31.8923.

  7. Leighl NB, Rekhtman N, Biermann WA, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol 2014;32(32):3673-3679. doi: 10.1200/JCO.2014.57.3055.

  8. Ettinger DS, Wood DE, Akerley W, et al. Non-small cell lung cancer, version 6.2015. J Natl Compr Canc Netw 2015;13(5):515-524. doi: 10.6004/jnccn.2015.0071.

  9. Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol 2017;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4.

  10. Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013;105(9):595-605. doi: 10.1093/jnci/djt072.

  11. Bulman W, Saqi A, Powell CA. Acquisition and processing of endobronchial ultrasound-guided transbronchial needle aspiration specimens in the era of targeted lung cancer chemotherapy. Am J Respir Crit Care Med 2012;185(6):606-611. doi: 10.1164/rccm.201107-1199CI.

  12. Jurado J, Saqi A, Maxfield R, et al. The efficacy of EBUS-guided transbronchial needle aspiration for molecular testing in lung adenocarcinoma. Ann Thorac Surg 2013;96(4):1196-1202. doi: 10.1016/j.athoracsur.2013.05.066.

  13. Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011;22(12):2616-2624. doi: 10.1093/annonc/mdr489.

  14. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: Implications for current and future therapies. J Clin Oncol 2013;31(8):1039-1049. doi: 10.1200/JCO.2012.45.3753.

  15. Amorín KE. Cáncer de pulmón, una revisión sobre el conocimiento actual, métodos diagnósticos y perspectivas terapéuticas. Rev perú med exp salud publica 2013;30(1):85-92.

  16. Dietz S, Sültmann H, Du Y, et al. Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy. Oncotarget 2017;8(43):74049-74057. doi: 10.18632/oncotarget.18200.

  17. NCCN guidelines version 3. 2018 Non-Small Cell Lung Cancer. Access date: 2018 March 14. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx.

  18. Varghese AM, Sima CS, Chaft JE, et al. Lungs don’t forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers. J Thorac Oncol 2013;8(1):123-125. doi: 10.1097/JTO.0b013e31827914ea.

  19. Mazza FD, Cappuzzo F. Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib. Appl Clin Genet 2017;10:49-56. doi: 10.2147/TACG.S103471.

  20. Wu YL, Saijo N, Thongprasert S, et al. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Lung Cancer 2017;104:119-125. doi: 10.1016/j.lungcan.2016.11.022.

  21. Zhang YL, Yuan JQ, Wang KF, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 2016;7(48):78985-78993. doi: 10.18632/oncotarget.12587.

  22. Martelli MP, Sozzi G, Hernandez L, Pettirossi V, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009;174(2):661-670. doi: 10.2353/ajpath.2009.080755.

  23. Kim H, Chung JH. Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement. Transl Lung Cancer Res 2015;4(2):149-155. doi: 10.3978/j.issn.2218-6751.2014.12.02.

  24. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated alk-positive non–small-cell lung cancer. N Engl J Med 2017;377(9):829-838. doi: 10.1056/NEJMoa1704795.

  25. Bubendorf L, Büttner R, Al-Dayel F, et al. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch 2016;469(5): 489-503. doi: 10.1007/s00428-016-2000-3.

  26. Zhao J, Li Q, Lin G, et al. Mutation profiling and treatment choosing of Chinese ROS1 positive advanced lung cancer patients. J Clin Oncol 2018. Access date: 2018 July 9. Avaible from: https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e21102.

  27. Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol 2017;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4.

  28. Jorge SE, Schulman S, Freed JA, et al. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer 2015;90(3):369-374. doi: 10.1016/j.lungcan.2015.10.028.

  29. Mar N, Vredenburgh JJ, Wasser JS. Targeting HER2 in the treatment of non-small cell lung cancer. Lung Cancer 2015;87(3):220-225. doi: 10.1016/j.lungcan.2014.12.018.

  30. Liu L, Li Y, Li S, et al. Comparison of next-generation sequencing systems. J Biomed Biotechnol 2012;2012:251364. doi: 10.1155/2012/251364.

  31. Tops BB, Normanno N, Kurth H, et al. Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. BMC Cancer 2015;15:26. doi: 10.1186/s12885-015-1015-5.

  32. D’Haene N, Le Mercier M, De Nève N, et al. Clinical validation of targeted next generation sequencing for colon and lung cancers. PLoS One 2015;10(9): e0138245. doi: 10.1371/journal.pone.0138245.


2020, Number 1

2020; 79 (1)